Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179436 · ClinicalTrials.gov registry record · Phase 1
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 415
- Enrollment target
NCT03179436: Completed Phase 1 study, sponsored by Merck Sharp & Dohme.
NCT03179436 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 415 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (592% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03179436, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 415 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
Primary Outcome
DLT was defined as toxicity that is possibly, probably, or definitely related to study therapy and may result in a change in the given dose. DLTs include Grade (Gr)4 non-hematologic toxicity (not laboratory); Gr 4 hematologic toxicity lasting ≥7 days (except thrombocytopenia); most non-hematologic AEs ≥ Gr 3 in severity; any Gr 3 or Gr 4 non-hematologic laboratory value that requires clinically significant medical intervention, leads to hospitalization, persists for \>1 week, or results in a dru
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Quavonlimab
- DRUG Pembrolizumab/Quavonlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2017-07-02 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 1 |
What the finished NCT03179436 record still lists
NCT03179436 is an interventional study that assigns participants to a tested intervention. The registered 415 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (592% higher).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03179436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03179436 about?
NCT03179436 is a clinical study titled "Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)". This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
What is the current status of trial NCT03179436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 415 participants. The study started on 2017-07-02. Estimated completion is 2024-04-08.
What interventions are being tested in trial NCT03179436?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Quavonlimab (BIOLOGICAL), Pembrolizumab/Quavonlimab (DRUG).
Who is sponsoring clinical trial NCT03179436?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03179436's enrollment target sits among peer trials
415 71st of 2000 higher than 1,930 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI